Phase
Condition
Melanoma
Treatment
N/AClinical Study ID
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Patients with operable metastatic melanoma (stage III or IV of American JointCommittee on Cancer [AJCC] Stages CLassification) treated with neoadjuvantimmunotherapy (anti-PD1 or anti-PD1 + anti-CTLA-4), even if surgery cancelled due todisease progression or complete response or patient's refusal to be operated.
Efficacy of the neoadjuvant immunotherapy histologically of radiologically assessed
Exclusion
Exclusion Criteria:
- Uveal melanoma
Study Design
Connect with a study center
CHU Angers
Angers,
FranceSite Not Available
CHU de Besançon
Besançon,
FranceActive - Recruiting
Hôpital Avicenne
Bobigny,
FranceSite Not Available
CH de Boulogne-sur-Mer
Boulogne-sur-Mer,
FranceSite Not Available
CHU Clermont-Ferrand
Clermont-Ferrand,
FranceSite Not Available
Centre de Lutte Contre le Cancer Léon Bérard
Lyon,
FranceSite Not Available
ICO René Gauducheau
Saint-Herblain,
FranceSite Not Available
Institut Universitaire de Cancérologie de Toulouse
Toulouse,
FranceSite Not Available
CH de Valence
Valence,
FranceSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.